(Bloomberg) — Eli Lilly & Co.’s relentless inventory data have Morgan Stanley analysts musing whether or not it should develop into the primary US firm exterior of the Magnificent Seven to achieve a market worth of $1 trillion.
Most Learn from Bloomberg
The analysts lifted their value goal on the weight-loss drugmaker to the very best on Wall Avenue on Friday, to a degree that may take the market capitalization to about $900 billion, in accordance with Bloomberg calculations.
“Might Lilly be the primary $1 trillion biopharma inventory?” Morgan Stanley’s Terence Flynn and colleagues requested in a be aware to shoppers. “We proceed to see a path for additional upside.”
Shares of the drugmaker climbed as a lot as 2.1% on Friday, to hit a contemporary file excessive. The inventory has jumped 32% this yr, bolstered by demand for its Mounjaro and Zepbound medication for diabetes and weight problems. That’s taken Lilly’s market capitalization to almost $730 billion, inserting it among the many 10 most dear firms within the S&P 500 Index.
Lilly’s market worth overtook that of Tesla Inc. final month following disappointing earnings and progress issues for the electric-car maker, which reached the $1 trillion mark in 2021 however has since fallen out of that choose group. The $1 trillion-plus membership now consists of Microsoft Corp., Apple Inc., Nvidia Corp., Alphabet Inc., Amazon.com Inc. and Meta Platforms Inc. The one non-tech firm with the next market cap than Lilly is Berkshire Hathaway Inc.
A number of analysts boosted their value targets on Lilly this month following upbeat earnings outcomes, together with these at Societe Generale SA, Jefferies and Barclays Plc, in accordance with information compiled by Bloomberg. Some, nevertheless, seem like betting that the optimism has already been priced in: Lilly shares closed at $757.78 on Thursday, in comparison with the common analyst value goal of $756.14.
The corporate’s blockbuster diabetes drug Mounjaro is usually used off-label for weight reduction, whereas Zepbound, which was not too long ago accepted for weight reduction, is predicted to develop into the best-selling drug in historical past.
–With help from James Cone and Angel Adegbesan.
(Updates with Friday buying and selling in fourth paragraph.)
Most Learn from Bloomberg Businessweek
©2024 Bloomberg L.P.
